Preterm labor. Preterm labor and delivery
Conditions
Interventions
Intervention 1: In case group, celecoxib capsules under the brand name Celebrex 100mg manufactured by Pfizer incorporations, Germany, at a dose of 100mg orally, initially, and then if the contractions
Treatment - Drugs
In case group, celecoxib capsules under the brand name Celebrex 100mg manufactured by Pfizer incorporations, Germany, at a dose of 100mg orally, initially, and then if the contractions continue, 100mg
In control group, Magnesium sulfate 50% vials manufactured by Samen incorporations will be used. Initial dose of 4 grams (equivalent to 8ml) and the maintenance dose of 2 grams per hour (equivalent to
Sponsors
Vice Chancellor for research, Kashan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
16 Years to 44 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: pregnant women diagnosed with preterm labor pains with 4 contractions during 20 minutes or 8 contractions in an hour and having the following conditions: 1.gestational age less than 34 weeks and more than 24 weeks 2.having live singleton fetus 3.dilatation of at least 1cm 4.no exclusion criteria Exclusion criteria: any of the following conditions: 1.ruptured amniotic membrane 2.symptoms/signs suggestive of placental detachment (decollement) 3.chorioamnionitis 4.entering the active phase of labor 5.conditions that disrupt the normal delivery process and lead to cesarean section or induction of the labor 6.no consent to participate or to continue the study by the pregnant women 7.sensitivity to the drug 8.hypertension 9.diabetes mellites 10.gastric ulcer
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Uterin contractions. Timepoint: Before intervention, 1,12 and 48 hours after intervention. Method of measurement: Contractions that last more than 30 seconds and is counted by the resident during a period of 20 minutes. | — |
Secondary
| Measure | Time frame |
|---|---|
| Delivery. Timepoint: 48 hours after intervention. Method of measurement: Evaluation of doing or not doing the delivery. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Fatemeh Foroozanfar
Kashan University of Medical Sciences
Outcome results
None listed